Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension.
Combined administration of inhaled nitric oxide and beraprost sodium resulted in a more intense decrease in pulmonary vascular resistance than nitric oxide given alone (mean -33% vs -45%, p <0.05), without serious systemic hypotension. Combined therapy with nitric oxide and beraprost sodium is highly desirable in treating primary and secondary pulmonary hypertension in children.
Ichida
F
F
Department of Pediatrics, Toyama Medical and Pharmaceutical University, Japan.
Uese
K
K
Tsubata
S
S
Hashimoto
I
I
Hamamichi
Y
Y
Fukahara
K
K
Murakami
A
A
Miyawaki
T
T
D002648:Child; D002675:Child, Preschool; D000242:Cyclic AMP / Q000097:blood; D006152:Cyclic GMP / Q000097:blood; D004357:Drug Synergism; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D007223:Infant; D008168:Lung / Q000187:drug effects / Q000502:physiology*; D009569:Nitric Oxide / Q000494:pharmacology*; D014655:Vascular Resistance; D014664:Vasodilation / Q000187:drug effects*; D014665:Vasodilator Agents / Q000494:pharmacology*
D014665:Vasodilator Agents; D009569:Nitric Oxide; C048081:beraprost; D011464:Epoprostenol; D000242:Cyclic AMP; D006152:Cyclic GMP